Vedolizumab Medicine 07 December 2021 Extended indication Treatment of adult patients with pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with, lost response to, or were intolerant to antibiotic therapy. Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Vedolizumab Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Bowel diseases Extended indication Treatment of adult patients with pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with, lost response to, or were intolerant to antibiotic therapy. Current proprietary name Already available biosimilars / generics Proprietary name Entyvio Manufacturer Takeda Portfolio holder Mechanism of action Immunosuppression Route of administration Intravenous Therapeutical formulation Powder for solution for infusion Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date June 2021 Expected Registration March 2022 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options anti-TNF, vedolizumab, ustekinumab, tofacitinib. Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Colitis ulcerosa komt steeds vaker voor met name in de westerse landen. Er zijn momenteel ruim 80.000 mensen in Nederland met een chronische darmontsteking. Dit is ongeveer 1 op de 200 mensen. Hiervan heeft iets meer dan de helft ulcerative colitis. Expected cost per patient per year Cost References https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/kostenoverzicht/modal/vedolizumab Additional remarks Entyvio, 300 mg poeder voor oplossing voor infusie 300 mg: € 2.298,80. Entyvio, 0,68 ml injectievloeistof 158,8 mg/ml: € 658,80 Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks